The following abstract is drawn from a recently published paper in Clinical Imaging. We invite you to read the full paper and join the conversation, become a member of the Pathology News community to share your thoughts, ask questions, and engage with others around this work.
Authors: Liliana Lighta, Miguel Penab, Sarah M. Pittmanb, Tie Liangb, Jafi A. Lipsonb, Eric L. Rosenb, Brittany Z. Dashevskyb
Abstract
Objective
To evaluate patient perspectives on breast cancer, risk assessment, and screening tools.
Methods
This IRB-approved HIPAA-compliant study included an anonymous 12-question survey administered to female patients at 4 medical clinics (2 radiology, 1 internal medicine and 1 gynecology) in Northern California during May–June 2024. Results were compared using Fisher exact tests between groups. A p-value of <0.05 was considered significant.
Results
Surveys were completed by 319 patients at radiology (160), gynecology (80) and internal medicine (79) clinics. On a scale of 1 (not concerned) to 5 (extremely concerned), 34.7% (111/319) reported 4 or 5 out of 5 concern for developing breast cancer. Among respondents not aware of their lifetime risk, 77.2% (85/110) were interested in obtaining a risk assessment. Most respondents (80.5% (257/319)) reported they would be comfortable with breast cancer risk assessment derived from their screening mammogram by AI-based methods, compared to 31.0% (99/319) using personal/family history obtained from a survey. Patients surveyed at gynecology and radiology offices preferred obtaining their risk results from their gynecologist (82.5% (66/80)) (p ≤ 0.001), (57.3% (90/157)) (p = 0.006), and patients surveyed at the internal medicine clinic (63.3% (50/79) (p = 0.081) preferred their PCP. If found to be at increased risk, 90.3% (288/319) of patients reported interest in additional screening tests. Most patients at increased breast cancer risk (72% (111/154)) reported interest in genetic testing, compared with 50% (84/165) of patients not at increased breast cancer risk (p = 0.001).
Conclusion
Patients demonstrated a strong interest in AI-based risk assessment using their screening mammogram, and those at higher risk expressed interest in additional breast cancer screening tools and genetic testing.
Read the full article: A multisite survey on patient perspectives of breast cancer risk assessment and supplemental breast cancer screening tools – Clinical Imaging
aHoward University Collge of Medicine, Washington, DC, United States of America
bStanford University School of Medicine, Department of Radiology, Stanford, CA, United States of America
